Relay Therapeutics, Inc. (RLAY)
Develops experimental cancer and genetic disease drugs using computer modeling to design better molecules.
$18.06-0.03%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+437.5%
The outlook
RLAY trades at $18.06, sitting well above both its 50- and 200-day moving averages and near the upper end of its 52-week range. Analyst consensus is strongly bullish with an average price target implying roughly 44% upside from current levels. The stock shows technical strength, though investors should note it's already elevated within its yearly trading band.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 13 analysts
Price trendAbove its 50- & 200-day averages
52-week range85% of the way from its 52-week low to high
Price targetAvg target +44% vs current price
Analyst price target
~12-month · 13 analysts$26.08average target+44.4% vs now
Now $18.06
Low $20.00High $32.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$3.94B
52-wk high
$20.79
52-wk low
$3.03
50-day avg
$16.49
200-day avg
$11.10
Trailing P/E
—